Potential new drugs for therapy of chronic obstructive pulmonary disease (Q35164728)

6 August 2017

1 reference

title

Potential new drugs for therapy of chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

6 August 2017

main subject

1 reference

de Boer WI

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

1067-1086

1 reference

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

New concepts in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Health outcomes of asthma and COPD patients: the evaluation of a project to implement guidelines in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Remodeling in asthma and chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Tumor Necrosis Factor- α Gene Polymorphism in Chronic Bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Inhaled corticosteroids and hip fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Rheumatoid arthritis: developing pharmacological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Biologic therapy of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Tumor necrosis factor-alpha +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Interleukin-10 and the interleukin-10 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The treatment of psoriasis with IL-10: rationale and review of the first clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Role of IL-10 for induction of anemia during inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Interleukin-1 receptor antagonist inhibits interleukin-8 expression in A549 respiratory epithelial cells infected in vitro with a replication-deficient recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Monoclonal antibodies as a strategy for pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Nicotinanilides as inhibitors of neutrophil chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Differential role of IFN-gamma-inducible protein 10 kDa in a cockroach antigen-induced model of allergic airway hyperreactivity: systemic versus local effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Targeting monocyte chemoattractant protein-1 signalling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Antiinflammatory and antiarteriosclerotic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Smoking cessation guidelines for health professionals: an update. Health Education Authority

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor-alpha (TNF-alpha) production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Synthesis and bioactivities of novel 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

The Selective CXCR2 Antagonist SB272844 Blocks Interleukin-8 and Growth-related Oncogene-α-mediated Inhibition of Spontaneous Neutrophil Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Systemic effects of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

CXCL8(3-73)K11R/G31P antagonizes the neutrophil chemoattractants present in pasteurellosis and mastitis lesions and abrogates neutrophil influx into intradermal endotoxin challenge sites in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.7.1067

Novel cytokine production inhibitors produced by a basidiomycete, Marasmiellus sp

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.54.703

Identifiers

DOI

10.1517/13543784.12.7.1067

1 reference

6 August 2017

1 reference